Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Myeloid 2Lymphoid 2Genitourinary 2Gastrointestinal 2CNS 2

Conditions

Prostatic Neoplasms 33Ovarian Neoplasms 9Breast Neoplasms 9Pancreatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Sarcoma 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms, Castration-Resistant 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hereditary Sensory and Autonomic Neuropathies 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Castration-Resistant Prostate Carcinoma 2Xanthogranuloma, Juvenile 1

Interventions

Vincristine 16Cyclophosphamide 16Filgrastim 13Etoposide 12Doxorubicin 12Radiotherapy 11Carboplatin 10X-Rays 9Dactinomycin 9Specimen Handling 8Phantoms, Imaging 8Magnetic Resonance Spectroscopy 8Granulocyte Colony-Stimulating Factor 8Temozolomide 6Melphalan 6Ifosfamide 6Topotecan 5Polymerase Chain Reaction 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Irinotecan 5Busulfan 5Biopsy 5sargramostim 4Stem Cell Transplantation 4Gene Expression Profiling 4Amplified Fragment Length Polymorphism Analysis 4Thiotepa 3Reverse Transcriptase Polymerase Chain Reaction 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Wilms Tumor × olaparib × Genitourinary × Clear all
NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled 12 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡